Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Oct;54(10):933-43.
doi: 10.1007/s00262-005-0678-1. Epub 2005 May 12.

Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans

Marie Robin  1 , Marie-Hélène Schlageter, Christine Chomienne, Rose-Ann Padua
Affiliations
Review

Targeted immunotherapy in acute myeloblastic leukemia: from animals to humans

Marie Robin et al. Cancer Immunol Immunother. 2005 Oct.

Abstract

Immunity against acute myeloid leukemia (AML) is demonstrated in humans by the graft-versus-leukemia effect in allogeneic hematopoietic stem cell transplantation. Specific leukemic antigens have progressively been discovered and circulating specific T lymphocytes against Wilms tumor antigen, proteinase peptide or fusion-proteins produced from aberrant oncogenic chromosomal translocations have been detected in leukemic patients. However, due to the fact that leukemic blasts develop various escape mechanisms, antileukemic specific immunity is not able to control leukemic cell proliferation. The aim of immunotherapy is to overcome tolerance and boost immunity to elicit an efficient immune response against leukemia. We review different immunotherapy strategies tested in preclinical animal models of AML and the human trials that spurred from encouraging results obtained in animal models, demonstrate the feasibility of immunotherapy in AML patients.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
DNA vaccination induce both humoral and cell-mediated immune response [87]. DNA can be taken up by a muscle cell, processed and the resulting protein shed as an antigen to be taken up by an antigen-presenting cell (APC) and presented in an MHC Class I restricted manner to CD8+ T cells to generate cytotoxic T-cells (CTL) and in an MHC Class II restricted manner to CD4+ T cells to promote Th1 and Th2 response
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921–1925. - PubMed
    1. Adler A, Chervenick PA, Whiteside TL, et al. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood. 1988;71:709–716. - PubMed
    1. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86–89. doi: 10.1038/32183. - DOI - PubMed
    1. Antoku K, Liu Z, Johnson DE. Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents. Leukemia. 1997;11:1665–1672. doi: 10.1038/sj.leu.2400805. - DOI - PubMed
    1. Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186–1193. doi: 10.1056/NEJM199810223391702. - DOI - PubMed